JAK kinase inhibitors for the treatment of acute lymphoblastic leukemia

Recent studies of acute lymphoblastic leukemia have identified activating mutations in components of the interleukin-7 receptor complex (IL7R, JAK1, and JAK3). It will be of interest to investigate both JAK1 and JAK3 kinase inhibitors as targeted agents for these leukemias.

Detalles Bibliográficos
Autores principales: Degryse, Sandrine, Cools, Jan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research Highlight
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545857/
https://www.ncbi.nlm.nih.gov/pubmed/26208852
http://dx.doi.org/10.1186/s13045-015-0192-7
_version_ 1782386799743598592
author Degryse, Sandrine
Cools, Jan
author_facet Degryse, Sandrine
Cools, Jan
author_sort Degryse, Sandrine
collection PubMed
description Recent studies of acute lymphoblastic leukemia have identified activating mutations in components of the interleukin-7 receptor complex (IL7R, JAK1, and JAK3). It will be of interest to investigate both JAK1 and JAK3 kinase inhibitors as targeted agents for these leukemias.
format Online
Article
Text
id pubmed-4545857
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-45458572015-08-23 JAK kinase inhibitors for the treatment of acute lymphoblastic leukemia Degryse, Sandrine Cools, Jan J Hematol Oncol Research Highlight Recent studies of acute lymphoblastic leukemia have identified activating mutations in components of the interleukin-7 receptor complex (IL7R, JAK1, and JAK3). It will be of interest to investigate both JAK1 and JAK3 kinase inhibitors as targeted agents for these leukemias. BioMed Central 2015-07-26 /pmc/articles/PMC4545857/ /pubmed/26208852 http://dx.doi.org/10.1186/s13045-015-0192-7 Text en © Degryse and Cools. 2015 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (http://creativecommons.org/publicdomain/zero/1.0) ) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Highlight
Degryse, Sandrine
Cools, Jan
JAK kinase inhibitors for the treatment of acute lymphoblastic leukemia
title JAK kinase inhibitors for the treatment of acute lymphoblastic leukemia
title_full JAK kinase inhibitors for the treatment of acute lymphoblastic leukemia
title_fullStr JAK kinase inhibitors for the treatment of acute lymphoblastic leukemia
title_full_unstemmed JAK kinase inhibitors for the treatment of acute lymphoblastic leukemia
title_short JAK kinase inhibitors for the treatment of acute lymphoblastic leukemia
title_sort jak kinase inhibitors for the treatment of acute lymphoblastic leukemia
topic Research Highlight
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545857/
https://www.ncbi.nlm.nih.gov/pubmed/26208852
http://dx.doi.org/10.1186/s13045-015-0192-7
work_keys_str_mv AT degrysesandrine jakkinaseinhibitorsforthetreatmentofacutelymphoblasticleukemia
AT coolsjan jakkinaseinhibitorsforthetreatmentofacutelymphoblasticleukemia

Ejemplares similares